Trials / Unknown
UnknownNCT05320913
Pericapsular Nerve Group (PENG) Block Combined With Periarticular Multimodal Drug Injection (PMDI) Versus Isolated PMDI for Pain Management After Total Hip Arthroplasty: a Randomized Controlled Trial
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 58 (estimated)
- Sponsor
- Yonsei University · Academic / Other
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
Adequate pain control after total hip arthroplasty is crucial for early ambulation and patient satisfaction. However, there is no consensus about optimal pain control after post operation. In general, the periarticular multimodal durg injection block has been done for pain control in primary total hip arthroplasty. The pericapsular nerve group (PENG) block has been recently introduced a new technique for blockade of the articular branches of the femoral, obturator and accessory obturator nerves. PENG block is possible to provide sufficient analgesia and preserve lower limb muscle strength. The investigators will compare PENG and PMDI block with isolated PMDI block in patients undergoing total hip arthroplasty.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Pericapsular nerve group(PENG) block combined with periarticular multimodal drug injection (PMDI) | periarticular local anesthetic infiltration with 120 mg of ropivacaine, epinephrine 0.2 mg and 30 mg of ketorolac diluted with normal saline to a total volume of 40 mL. + PENG block with ropivacaine 40 mg and epinephrine 0.1 mg with normal saline to a total volume of 20 mL |
| PROCEDURE | isolated periarticular multimodal drug injection (PMDI) | periarticular local anesthetic infiltration with 150 mg of ropivacaine, epinephrine 0.3 mg and 30 mg of ketorolac diluted with normal saline to a total volume of 50 mL |
Timeline
- Start date
- 2022-04-04
- Primary completion
- 2023-12-13
- Completion
- 2023-12-13
- First posted
- 2022-04-11
- Last updated
- 2022-05-03
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05320913. Inclusion in this directory is not an endorsement.